[
  {
    "ts": "2026-02-09T02:00:00+00:00",
    "headline": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China",
    "summary": "TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi",
    "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-020000510.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "56195ee9-f62d-3cf6-99d1-2486ecc381ff",
      "content": {
        "id": "56195ee9-f62d-3cf6-99d1-2486ecc381ff",
        "contentType": "STORY",
        "title": "Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China",
        "description": "",
        "summary": "TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi",
        "pubDate": "2026-02-09T02:00:00Z",
        "displayTime": "2026-02-09T02:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d",
          "originalWidth": 865,
          "originalHeight": 290,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IDD9DHtEaM8wc.4J0e2kkA--~B/aD0yOTA7dz04NjU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 865,
              "height": 290,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iODOrgJZ_MV95T9B.jt0vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8db71a830aa632e702f24ebd736c00d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-020000510.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biologics-license-application-subcutaneous-formulation-020000510.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "ESAIY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T16:40:56+00:00",
    "headline": "Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says",
    "summary": "Biogen (BIIB) demonstrated solid commercial execution across its core franchises, supporting a clear",
    "url": "https://finance.yahoo.com/news/biogen-sales-execution-growth-support-164056267.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "bb9b6f3b-fb13-3466-bc58-e6564c5a2938",
      "content": {
        "id": "bb9b6f3b-fb13-3466-bc58-e6564c5a2938",
        "contentType": "STORY",
        "title": "Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says",
        "description": "",
        "summary": "Biogen (BIIB) demonstrated solid commercial execution across its core franchises, supporting a clear",
        "pubDate": "2026-02-09T16:40:56Z",
        "displayTime": "2026-02-09T16:40:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-sales-execution-growth-support-164056267.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-sales-execution-growth-support-164056267.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-09T16:38:00+00:00",
    "headline": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
    "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
    "url": "https://finance.yahoo.com/news/5-drug-bigwigs-surpass-q4-163800508.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "aec30b43-0d70-317c-b6bb-2d4b849ada6c",
      "content": {
        "id": "aec30b43-0d70-317c-b6bb-2d4b849ada6c",
        "contentType": "STORY",
        "title": "Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?",
        "description": "",
        "summary": "Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.",
        "pubDate": "2026-02-09T16:38:00Z",
        "displayTime": "2026-02-09T16:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890",
          "originalWidth": 620,
          "originalHeight": 393,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/owRrQw..RZz13mqQwVBgRA--~B/aD0zOTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890.cf.webp",
              "width": 620,
              "height": 393,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xvPk7PEgDBlSHxNlV1Nayw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a0e141116a5c1fff5e57140486a1890.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-drug-bigwigs-surpass-q4-163800508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-drug-bigwigs-surpass-q4-163800508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]